Non-Small Cell Lung Cancer
Conditions
Keywords
Non-small cell lung carcinoma, NSCLC, Treatment of lung cancer, Lung cancer, Lung adenocarcinoma, Squamous cell lung carcinoma, Large-cell lung carcinoma, Non small cell lung carcinoma, Non small cell lung cancer, Non-small cell lung cancer, Large cell lung carcinoma, Large cell lung cancer, MET Exon 14 skipping, skipping, Exon 14
Brief summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to INC280, Capmatinib
Detailed description
CINC280A02001M - No longer available - Managed Access Program (MAP) Cohort Treatment Plan CINC280A02001M to provide access to Capmatinib, for MET Exon 14 skipping Non-Small Cell Lung Cancer (NSCLC)
Interventions
DRUGCapmatinib
Tablet for oral use
Sponsors
Novartis Pharmaceuticals
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
An independent request was received from a licensed physician. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment. The patient is not eligible or able to enrol in a clinical trial or continue participation in such trial. There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated. The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable). Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program. Managed Access provision is allowed per local laws/regulations.
Outcome results
None listed